• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Commercial Officer Wiley Matthew T. sold $129,101 worth of shares (2,867 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 174,633 units (SEC Form 4) (withholding obligation)

    6/26/26 4:30:03 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $DFTX alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    X
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Wiley Matthew T.

    (Last)(First)(Middle)
    C/O DEFINIUM THERAPEUTICS, INC.
    ONE WORLD TRADE CENTER, SUITE 8500

    (Street)
    NEW YORK NEW YORK 10007

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Definium Therapeutics, Inc. [ DFTX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director10% Owner
    XOfficer (give title below)Other (specify below)
    Chief Commercial Officer
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    06/25/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Common Shares06/25/2026S(1)2,867D$45.03174,633D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    1. Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on May 29, 2025.
    /s/Mark Sullivan, Attorney-in-Fact for Matthew T. Wiley06/26/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $DFTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DFTX

    DatePrice TargetRatingAnalyst
    6/23/2026$38.00 → $50.00Buy
    Needham
    4/17/2026$30.00Buy
    Stifel
    4/10/2026$49.00Overweight
    Piper Sandler
    2/24/2026$25.00Outperform
    Wolfe Research
    1/30/2026$30.00Buy
    Jefferies
    More analyst ratings

    $DFTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham reiterated coverage on Definium Therapeutics with a new price target

    Needham reiterated coverage of Definium Therapeutics with a rating of Buy and set a new price target of $50.00 from $38.00 previously

    6/23/26 7:52:49 AM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    Stifel initiated coverage on Definium Therapeutics with a new price target

    Stifel initiated coverage of Definium Therapeutics with a rating of Buy and set a new price target of $30.00

    4/17/26 8:10:40 AM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    Piper Sandler initiated coverage on Definium Therapeutics with a new price target

    Piper Sandler initiated coverage of Definium Therapeutics with a rating of Overweight and set a new price target of $49.00

    4/10/26 8:31:32 AM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    $DFTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Sullivan Mark sold $585,750 worth of shares (13,008 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 320,571 units (SEC Form 4) (withholding tax)

    4 - Definium Therapeutics, Inc. (0001813814) (Issuer)

    6/26/26 4:30:10 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Medical Officer Karlin Daniel sold $451,876 worth of shares (10,035 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 503,282 units (SEC Form 4) (withholding obligation)

    4 - Definium Therapeutics, Inc. (0001813814) (Issuer)

    6/26/26 4:30:04 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Financial Officer Roberts Brandi sold $135,675 worth of shares (3,013 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 209,487 units (SEC Form 4) (withholding obligation)

    4 - Definium Therapeutics, Inc. (0001813814) (Issuer)

    6/26/26 4:30:07 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    $DFTX
    SEC Filings

    View All

    SEC Form 144 filed by Definium Therapeutics Inc.

    144 - Definium Therapeutics, Inc. (0001813814) (Subject)

    6/25/26 4:10:23 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 144 filed by Definium Therapeutics Inc.

    144 - Definium Therapeutics, Inc. (0001813814) (Subject)

    6/25/26 4:09:36 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 144 filed by Definium Therapeutics Inc.

    144 - Definium Therapeutics, Inc. (0001813814) (Subject)

    6/25/26 4:08:06 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    $DFTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening

    Issued on behalf of Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP)NEW YORK and TORONTO, July 21, 2026 /CNW/ -- USA News Group - News Commentary - Depression remains one of the most stubborn problems in modern medicine, and the numbers behind it are staggering. Tens of millions of adults live with major depressive disorder, and the majority never reach full remission on the first medication they try. That persistent treatment gap has drawn a wave of biotech and pharmaceutical companies into what is now one of the most closely watched races in interventional psychiatry, each pursuing a different way to reach patients that current antidepressants leave behind.

    7/21/26 9:00:00 AM ET
    $CMPS
    $DFTX
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products

    Definium Therapeutics Announces New Employee Inducement Grants

    Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to two newly hired non-executive employees consisting of options to purchase an aggregate of 30,330 common shares of the Company (the "Options") with effective grant dates of July 20, 2026. The Options have an exercise price equal to the closing price of Definium’s common shares on the date of the grants, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and t

    7/20/26 4:01:00 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time

    Issued on behalf of Helus Pharma™Eli Lilly's agreement to acquire AtaiBeckley for up to $3.8 billion hands psychedelic medicine its first large-cap validation, and it lands on a late-stage cohort already carrying pivotal data into the back half of 2026, among them Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), which has a Phase 3 readout due in the fourth quarterUSA News Group News CommentaryNEW YORK, July 17, 2026 /CNW/ -- For half a century, psychedelic medicine was the field serious money would not touch. That ended this morning. Eli Lilly and Company (NYSE:LLY) agreed to acquire AtaiBeckley Inc. (NASDAQ:ATAI) for $6.75 per share in cash, roughly $2.8 billion, plus up to $2.50 per share in

    7/17/26 8:50:00 AM ET
    $ATAI
    $CMPS
    $DFTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products

    $DFTX
    Leadership Updates

    Live Leadership Updates

    View All

    Definium Therapeutics Appoints Roger Adsett to Board of Directors

    Seasoned biopharmaceutical leader brings deep commercial, operational, and launch expertise to support Definium's next phase of growth Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) today announced the appointment of Roger Adsett to its Board of Directors effective immediately. "We are thrilled to welcome Roger to our Board of Directors," said Rob Barrow, Chief Executive Officer of Definium Therapeutics. "Roger is a respected and proven leader with deep experience building high-performing commercial organizations and guiding transformational therapies from launch to meaningful market impact. At Insmed, he's led the development of world-class commercial and operation

    1/29/26 7:00:00 AM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    $DFTX
    Financials

    Live finance-specific insights

    View All

    Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

    Three Phase 3 topline data readouts for DT120 ODT expected in the coming months DT120 ODT program expanded into PTSD with Phase 3 Haven study expected to initiate in 2027 $373.4 million in cash, cash equivalents, and investments as of March 31, 2026, expected to fund operations into 2028 Conference call scheduled today at 4:30 p.m. EDT Definium Therapeutics, Inc. ("Definium" or the "Company") (NASDAQ:DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today reported financial results for the quarter ended March 31, 2026, and recent highlights. "After an

    5/7/26 4:01:00 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026

    Definium Therapeutics, Inc. (NASDAQ:DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a live webcast at 4:30 p.m. EDT on Thursday, May 7, 2026 to report financial results for the first quarter ended March 31, 2026, and discuss recent business highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the Definium Therapeutics website, ir.definiumtx.com, a

    4/30/26 4:01:00 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care

    Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates

    Emerge (Phase 3 MDD) enrollment complete; topline data anticipated in late 2Q 2026 Voyage (Phase 3 GAD) approximately 80% enrolled; no change in sample size required; topline readout anticipated in early 3Q 2026 Panorama (Phase 3 GAD) enrollment on track; topline readout expected in 2H 2026 $411.6 million in cash, cash equivalents and investments as of December 31, 2025 expected to fund operations into 2028 Conference call scheduled today at 4:30 p.m. EST Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorder

    2/26/26 4:01:00 PM ET
    $DFTX
    Medicinal Chemicals and Botanical Products
    Health Care